Alt-protein

Wildtype

40Mixed / Improving

San Francisco, CA, USFounded 20160 followers

www.wildtypefoods.com

Produces FDA-cleared cultivated coho salmon by growing Pacific salmon cells in bioreactors that mimic wild fish physiology, targeting restaurant markets as the first approved cultivated seafood in the US.

Green Score

40/100
Mixed / Improving
Greenwashing risk
medium
Data confidence
low
Method
how it is calculated
Climate Impact & Solution35%52

Does the core business genuinely avoid or reduce emissions, or build climate resilience? Share of revenue that is actually 'green'. Fossil-dependent models score low.

Cultivated salmon theoretically avoids wild-catch depletion and open-ocean aquaculture pollution, but no published independent LCA exists for Wildtype specifically, and sector-level research warns that bioreactor energy use for cooling could negate emissions gains versus conventional farmed salmon unless the facility runs on clean electricity.

Decarbonization & Targets20%10

Credible, science-based targets (SBTi), a real net-zero plan with progress to date, and CDP disclosure — not just a dated press release.

No SBTi commitment, no CDP disclosure, and no publicly stated net-zero or near-term science-based emissions target found for Wildtype; the company makes sustainability claims in marketing but has disclosed no quantified, time-bound reduction targets.

ESG & Operations15%38

Operational footprint, labour and social practices, and governance quality across the company's own operations and supply chain.

Wildtype is a small pre-revenue-scale startup (~81 employees) with no published sustainability report, no disclosed supply-chain labour standards, no board-level ESG governance documentation, and no third-party social audit; the cell-culture process avoids fishery bycatch and antibiotic use but operational environmental footprint data is absent.

Transparency & Verification15%20

Quality of disclosure, independent third-party verification, and how much hard data backs the company's claims.

No independent LCA, no sustainability report, no CDP filing, and no third-party verified emissions data have been identified; the company's climate claims are marketing-grade rather than disclosure-grade, and GFI has noted that no robust environmental assessments comparing alternative seafood to conventional counterparts had been published as of the most recent sector review.

Integrity15%72

Controversies, litigation, pollution, fossil-fuel lobbying, conflict-zone involvement and governance scandals. Higher means cleaner.

No pollution incidents, financial fraud, or governance scandals found; Wildtype has actively opposed state bans on cultivated meat through public testimony and litigation, which reflects advocacy consistent with its mission rather than misconduct, though heavy reliance on litigation to access markets is a business-continuity risk.

Why it's on ClimateTicker

Wildtype's cultivated coho salmon has genuine mitigation potential by eliminating wild-catch overfishing pressure and avoiding the pollution, escapee risks, and antibiotic use of conventional aquaculture. However, the environmental case rests on unverified assumptions about bioreactor energy intensity at commercial scale — published LCA research flags that energy use for bioreactor operation and cooling could make cultivated seafood more carbon-intensive than conventional farmed fish unless powered by renewables. Until Wildtype publishes an independent, peer-reviewed LCA for its own process, the climate thesis is plausible but not proven.

mitigationWildtype sells FDA-cleared cultivated Pacific salmon (grown from fish cells in bioreactors, combined with plant-based scaffolding) to fine-dining restaurants at premium price points, targeting initial markets across Oregon, California, Washington, Colorado, and Texas before a broader commercial rollout.

Controversy & Greenwashing Watch

lowNo independent LCA — climate claims unverified

Wildtype markets its product as environmentally superior to conventional salmon but has published no independent lifecycle assessment; sector research warns bioreactor energy intensity could exceed conventional aquaculture emissions at commercial scale without clean energy sourcing.gfi.org

mediumSector-wide investment collapse raises going-concern risk

Cultivated meat and seafood investment fell 75% in 2023 and another 40% in 2024 to just $139M industry-wide, with Wildtype's most recent major raise being a $100M Series B in 2022, raising questions about runway and scale-up viability.greenqueen.com.hk

mediumState bans on cultivated meat restrict market access

Seven US states have enacted bans on cultivated meat sales, forcing Wildtype to exit or avoid those markets and join litigation challenging the laws as unconstitutional — creating significant regulatory and commercial uncertainty.fooddive.com

Community Reviews

No reviews yet. Be the first to share your experience!

ClimateTicker assessments are evidence-based research, not investment advice. Companies and readers can challenge a factual claim or submit better evidence.